| NCT ID | NCT05387863 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Kidney Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-09-12 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2022-09-12 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.
Eligibility Criteria
Inclusion Criteria: * Male and female post-op and pre-op patients, ages 18 and older, diagnosed with a localized renal tumor up to 4 cm in diameter. * Patients scheduled for standard-of-care clinical exams with the NYU Urology Department Exclusion Criteria: * Stage IV cancer of any type * Inability to provide informed consent * Vulnerable subjects will not be recruited
Contact & Investigator
Stella Kang, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT05387863 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05387863 currently recruiting?
Yes, NCT05387863 is actively recruiting participants. Contact the research team at Stella.kang@nyulangone.org for enrollment information.
Where is the NCT05387863 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05387863 clinical trial?
NCT05387863 is sponsored by NYU Langone Health. The principal investigator is Stella Kang, MD at NYU Langone Health. The trial plans to enroll 40 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.